Zaicom Research Plus Sister Company Acquisition Doubles Regulatory Offering
Horsham, UK. (PRWEB UK) 4 September 2013 -- The new group will trade exclusively as Spectrum under the leadership of Managing Director, Dr Angela Gisby. “We are extremely pleased to have achieved such a smooth transaction to create one of the industry’s leading clinical, regulatory and pharmacovigilance providers. Our clients, large and small, can look forward to the benefits stemming from our increased size in terms of overall service offering, expanded capabilities and added value” said Dr Gisby.
The deal creates a formidable new force in this highly specialised sector of pharmaceutical support service, by leveraging Spectrum’s broad portfolio of clients and Quantum’s solid reputation in complimentary service offerings.
“This acquisition is exciting news for the whole group as it heralds Zaicom’s first move in an ambitious expansion plan in which it aims to become a £multi-million a year healthcare communications group by 2017. We already know that Zaicom Research Plus has benefitted from market research work for Spectrum’s regulatory, manufacturing and packaging clients and the addition of the Quantum team can only benefit our global business further, giving us more penetration in this key sector ” added Zaicom International group CEO, Graeme Chrystal.
Spectrum Regulatory Solutions
Spectrum was established in 2005, as part of the Zaicom International group of companies and provides clinical, regulatory and pharmacovigilance consultancy to the healthcare industry. This comprises a suite of services which support manufacturers during the run-up to obtaining marketing approval, and in post-marketing activities. Spectrum’s experience covers prescription, consumer, orphan drugs, nutraceuticals, cosmeceuticals as well as medical devices.
Spectrum has gained a reputation for quality, reliability and responsiveness. To maintain its leadership position, Spectrum recently successfully obtained ISO 9001:2008 certification.
Zaicom Research Plus
Zaicom Research Plus (ZRP) specializes in healthcare market research working with global and regional headquarters. Its reputation has been gained by achieving deeper insights derived from the use of advanced techniques and methodologies such as psychographics, heuristics, LAB profiling, ethnography, transactional analysis and root cause analysis. Clients benefit too from ZRP’s unique ability to call upon the knowledge and skills of the highly qualified scientific communications, market access, regulatory and commercialisation expertise provided by its sister companies.
Quantum
Quantum Medical has been an industry-leading provider of clinical, regulatory and pharmacovigilance medical writing, training, consultancy and project management for 15 years. “Quantum has been working alongside a small number of large global pharmaceutical, consumer health and animal health organisations. We now look forward to playing our part in the growth of Spectrum, and of the wider Zaicom International group, by providing an extended range of services and a complimentary portfolio of clients” said Alan Nicolle, Managing Director, Quantum.
Quantum was part of the Interlace Global Group which is now comprised of three industry-leading medical communications companies supporting leading global pharmaceutical companies – Wells Healthcare (WHC), Interlace Communications and WHC Inc operating in the USA.
Owner and Group Managing Director of Interlace Global Group Mark Forbes Irving said “Following a strategic review of our global business we’ve made the decision to focus our activities where we see most growth and opportunity, specifically in the fast developing eMedia field where we have unique digital training and interactive e-learning capabilities that are valued by our clients. This will provide an offering that complements our traditional areas of strength – strategic consultancy, publication and communication planning, writing, advocacy development, live events, strategic advisory boards, creative services, clinical trial support and bespoke market access programmes. This divestment and creation of the Quantum and Spectrum combined business therefore makes a lot of sense for us right now”.
Contact
Ellie Coutts – Marketing Executive
ecoutts(at)zaicom(dot)com
+44 (0)1403 320220
http://www.zaicom.com
http://www.spectrumrs.com
Follow
Twitter: @SpectrumRS
Google+: Spectrum Regulatory Solutions
Ellie Coutts - Marketing Executive, Spectrum Regulatory Solutions, http://www.spectrumrs.com, +44 1403 320220, [email protected]
Share this article